[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intrathecal-anesthesia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intrathecal-anesthesia":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100588813",false,"NCT06946277","Assessing the Time-Course of Dexmedetomidine-Induced Analgesia Via EEG","Mapping the Temporal Profile of Dexmedetomidine-Induced Analgesia Via EEG Signatures in Brain","Inclusion Criteria:\n\nPatients with hip osteoarthritis scheduled for total hip arthroplasty under intrathecal anesthesia; Age 18-70 years; American Society of Anesthesiologists (ASA) physical status classification I-III; Body mass index (BMI) 22-30 kg\u002Fm².\n\nExclusion Criteria:\n\nPre-existing peripheral or central nervous system disorders; Mental disorders; Cognitive impairment; Emergency surgery; or Hearing impairment.","ALL","18 Years","70 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Objective: To investigate the temporal dynamics of dexmedetomidine's analgesic effects in the brain using EEG.\n\nMethods: Eligible patients scheduled for total hip arthroplasty under intrathecal anesthesia received a continuous infusion of DEX at 1.5 μg\u002F(kg·h) for 15 minutes before neuraxial puncture, followed by an additional 15-minute infusion. The study was divided into three phases:\n\nPhase 1: Non-dosing phase (Baseline). Phase 2: DEX preemptive analgesia phase (DEX infusion). Phase 3: DEX cessation phase (Post-infusion).\n\nOutcomes:\n\nPrimary safety outcome: EEG spectral analysis at different phases. Secondary outcomes: NRS scores, postoperative nausea and vomiting (PONV), dizziness, agitation, and time to intestinal exhaust within 48 hours. Intraoperative hemodynamics were also monitored.",[26,27,28],"Total Hip Arthroplasty (THA)","Intrathecal Anesthesia","Hip Osteoarthritis","NOT_YET_RECRUITING","2025-04-23",{"date":32,"type":33},"2025-04-27","ACTUAL",{"date":35,"type":20},"2025-04-25",{"date":37,"type":20},"2025-05-26",{"name":39,"class":40},"China International Neuroscience Institution","OTHER",""]